Ddreg Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 24-06-2024
- Paid Up Capital ₹ 0.10 M
as on 24-06-2024
- Company Age 11 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -76.69%
(FY 2020)
- Profit 68.88%
(FY 2020)
- Ebitda 69.06%
(FY 2020)
- Net Worth -26.89%
(FY 2020)
- Total Assets -62.68%
(FY 2020)
About Ddreg Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Lokesh Pant and Neeraj Pant serve as directors at the Company.
- CIN/LLPIN
U74900HR2013PTC050377
- Company No.
050377
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
13 Sep 2013
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Gurgaon, Haryana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Ddreg Life Sciences Private Limited offer?
Ddreg Life Sciences Private Limited offers a wide range of products and services, including Turnkey Consultants & Solutions, Project Management, Business Planning and Management, Business Consultant, Copywriting & Content Development, Content Writing Service, Newspaper & Magazine Publishers, Publishing House, Film & Media Production Services, Multimedia Solutions.
Who are the key members and board of directors at Ddreg Life Sciences?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Lokesh Pant  | Director | 13-Sep-2013 | Current |
| Neeraj Pant | Director | 13-Sep-2013 | Current |
Financial Performance and Corporate Structure Insights of Ddreg Life Sciences.
Ddreg Life Sciences Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 76.69% decrease. The company also saw a substantial improvement in profitability, with a 68.88% increase in profit. The company's net worth observed a substantial decline by a decrease of 26.89%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Ddreg Life Sciences?
In 2020, Ddreg Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Ddreg Life Sciences?
Unlock and access historical data on people associated with Ddreg Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Ddreg Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Ddreg Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
